What are the alternatives to 3% diclofenac (Voltaren) topical solution?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Alternatives to 3% diclofenac include 5-fluorouracil and imiquimod, which are recommended as field treatments for actinic keratosis with moderate to strong evidence 1. These medications have been shown to be effective in treating actinic keratosis, with 5-fluorouracil demonstrating a complete clearance rate of 77% in individual AKs 1. Imiquimod, on the other hand, has been shown to have a complete clearance rate of 50% in a meta-analysis of five RCTs 1. Other alternatives may include cryosurgery, photodynamic therapy, and ingenol mebutate, which have been conditionally recommended for the treatment of actinic keratosis 1. Some key points to consider when choosing an alternative to 3% diclofenac include:

  • The strength of evidence supporting the use of each alternative, with 5-fluorouracil and imiquimod having moderate to strong evidence 1
  • The potential side effects and risks associated with each alternative, such as the cardiovascular and gastrointestinal risks associated with NSAIDs 1
  • The individual patient's medical history and comorbidities, which may affect the choice of alternative treatment
  • The need for careful counseling and monitoring of patients to anticipate and manage potential side effects, particularly with imiquimod 1. It is essential to consult with a healthcare provider before changing medications, especially for patients with cardiovascular, renal, or gastrointestinal conditions, as NSAIDs carry different risk profiles depending on the specific drug and medical history 1.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Alternatives to 3% Diclofenac

Alternatives to 3% diclofenac for the treatment of actinic keratosis include:

  • Topical 5-fluorouracil (5-FU) 2, 3, 4, 5, 6
  • Imiquimod 2, 3, 4, 5, 6
  • Photodynamic therapy (PDT) 2, 3, 4, 6
  • Cryotherapy 3, 5, 6
  • Ingenol mebutate (IMB) 3
  • Trichloroacetic acid (TCA) 3
  • Ablative fractional laser (AFXL) 3
  • Nicotinamide and acitretin for chemoprevention 4
  • Tirbanibulin ointment, which has shown promising aesthetic outcomes, including skin lightening and a reduction in mottled pigmentation 2

Efficacy Comparison

The efficacy of these alternatives compared to 3% diclofenac varies:

  • 5-FU is regarded as the most effective therapy for actinic keratosis 4
  • PDT has emerged as a highly effective treatment, demonstrating improved collagen synthesis, skin texture, and pigmentation 2
  • Imiquimod has been shown to enhance dermal fibroplasia and reduce solar elastosis 2
  • Cryotherapy is recommended for treating single AK lesions 5
  • Diclofenac has been found to be less efficacious than 5% 5-FU, 3.75-5% imiquimod, and photodynamic light therapy, despite its favorable side effect profile 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of actinic keratosis: a systematic review.

Archives of dermatological research, 2023

Research

Conventional treatment of actinic keratosis: an overview.

Current problems in dermatology, 2015

Research

Guidelines of care for the management of actinic keratosis: Executive summary.

Journal of the American Academy of Dermatology, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.